$46.99
2.71%
Nasdaq, Nov 20, 03:59 pm EST. Closed.
ISIN
US89422G1076
Symbol
TVTX

Travere Therapeutics Inc Stock price

$47.00
-5.30 10.13% 1M
+3.51 8.07% 6M
+8.79 23.00% YTD
+12.27 35.33% 1Y
+41.25 717.39% 3Y
+17.61 59.92% 5Y
+25.78 121.49% 10Y
+46.99 522,122.22% 20Y
Nasdaq, Closing price Fri, Nov 20 2026
-1.30 2.69%
ISIN
US89422G1076
Symbol
TVTX
Industry

Is Travere Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$4.2b
Enterprise Value
$4.3b
Net debt
$131.7m
Cash
$471.8m
Shares outstanding
95.7m
Valuation
P/E
negative
P/S | estimate
6.5 | 5.4
EV/Sales | estimate
6.7 | 5.6
EV/FCF | ex SBC
negative | negative
P/B
186.1
Financial Health
Equity Ratio
19.0%
Return on Equity
-22.3%
ROCE
-3.2%
ROIC
-5.5%
Debt/Equity
26.7
Share-Based Compensation & Dilution
SBC | % of Revenue
$72.8m | 11.2%
SBC as % of FCF
-
SBC Growth 1Y
70.9%
Share Count Growth 1Y
6.9%
Shareholder Yield
-6.9%
Financials
Revenue | estimate
$651.0m | $772.8m
EBITDA
$30.8m
EBIT
$-20.4m
Net Income
$-121.5m
Free Cash Flow | ex SBC
$-27.4m | $-100.2m
Growth
Revenue | estimate
49.4% | 57.5%
EBITDA
184.2%
EBIT
77.3%
Net Income
-37.2%
Free Cash Flow
74.5%
Margin
Gross
98.1%
EBITDA
4.7%
EBIT
-3.1%
Net
-18.7%
Free Cash Flow | ex SBC
-4.2% | -15.4%
More
EPS
$-1.3
FCF per Share
$-0.3
Short interest
12.9%
Employees
497
Rev per Employee
$990.0k

Travere Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Travere Therapeutics Inc forecast:

19x Buy
90%
2x Hold
10%

Analyst Opinions

21 Analysts have issued a Travere Therapeutics Inc forecast:

Buy
90%
Hold
10%

Travere Therapeutics Inc Events

Past Events
NOV
16
UBS Global Biopharma Conference 2026
6 days ago
NOV
2
Q3 2026 Earnings Call
19 days ago
AUG
4
Q2 2026 Earnings Call
4 months ago
JUN
8
Goldman Sachs 47th Annual Global Healthcare Conference 2026
6 months ago
JUN
2
Special Call - Travere Therapeutics, Inc.
6 months ago
MAY
13
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
4
Q1 2026 Earnings Call
7 months ago
APR
13
Special Call - Travere Therapeutics, Inc.
7 months ago
FEB
19
Q4 2025 Earnings Call
9 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
OCT
30
Q3 2025 Earnings Call
about one year ago

Financial data from Travere Therapeutics Inc

Sep '26
+/-
%
651 651
49% 49%
100%
- Direct Costs 13 13
23% 23%
2%
638 638
50% 50%
98%
- Selling and Administrative Expenses 359 359
42% 42%
55%
- Research and Development Expense 246 246
17% 17%
38%
31 31
184% 184%
5%
- Depreciation and Amortization 51 51
4% 4%
8%
EBIT (Operating Income) EBIT -20 -20
77% 77%
-3%
Net Profit -122 -122
37% 37%
-19%

In millions USD.

Don't miss a Thing! We will send you all news about Travere Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Travere Therapeutics Inc Stock News

Neutral
Business Wire
●
9 days ago
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on November 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 65,520 shares of its common stock. These inducement RSUs are subject to the terms of...
Negative
Investors Business Daily
●
19 days ago
Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug, Filspari.
More Travere Therapeutics Inc News

Company Profile

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Head office United States
CEO Dr. Dube
Employees 497
Founded 2008
Website travere.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today